Form 4: Ligand Pharma Invests $9M in Pelthos Convertible Note

Ligand Pharmaceuticals Inc. acquired a $9 million senior secured convertible note in Pelthos Therapeutics Inc., convertible into common stock at $34.442 per share.

Summary

• Ligand Pharmaceuticals Inc. (the Reporting Person) acquired a Senior Secured Convertible Note from Pelthos Therapeutics Inc. (the Issuer).
• The aggregate principal amount of the Convertible Note is $9 million.
• The Convertible Note may be converted into Pelthos Therapeutics Inc. Common Stock at a conversion price of $34.442 per share.
• The note includes a beneficial ownership limitation of 49.9% for Ligand Pharmaceuticals Inc.
• Ligand Pharmaceuticals Inc. is identified as both a Director and a 10% Owner of Pelthos Therapeutics Inc.
• The transaction occurred on November 6, 2025.

Sentiment

Score: 5

Explanation: The filing is a factual report of an insider transaction, indicating a strategic investment by a director and 10% owner. While providing capital to the issuer, it does not contain information to significantly sway sentiment positively or negatively without further context on the issuer's performance or strategic plans.

Positives

• Pelthos Therapeutics Inc. secured $9 million in financing through the issuance of a senior secured convertible note.
• Ligand Pharmaceuticals Inc. made a strategic investment in Pelthos Therapeutics Inc., a company where it holds a significant ownership stake and board representation.
• The senior secured nature of the note provides a level of protection for Ligand Pharmaceuticals Inc.'s investment.

Negatives

• The issuance of a convertible note by Pelthos Therapeutics Inc. introduces potential future dilution for existing common shareholders if the note is converted into equity.

Future Outlook

NA

Industry Context

This transaction represents an insider investment, a common occurrence in the biotech sector where strategic alliances and financing rounds often involve existing stakeholders and can provide necessary capital for research and development or operational expansion.

Related Party Transactions

• Ligand Pharmaceuticals Inc., which is a 10% owner and has its CEO and Senior Vice President of Investment Operations serving on the board of directors of Pelthos Therapeutics Inc., acquired a $9 million senior secured convertible note from Pelthos Therapeutics Inc.

Stakeholder Impact

• Shareholders of Pelthos Therapeutics Inc. may experience potential future dilution if the convertible note is exercised, but the company benefits from a $9 million capital infusion.
• Shareholders of Ligand Pharmaceuticals Inc. see an investment in a related entity, with potential returns from the note's interest or conversion.
• Other creditors of Pelthos Therapeutics Inc. might be impacted by the 'senior secured' nature of the note, which typically grants it priority in repayment over unsecured debt.

Key Dates

Recommendation

The filing reports a financing event where a significant shareholder and director acquired a convertible note. While providing capital to Pelthos, it also introduces potential future dilution. For Ligand, it represents an investment in a related entity. Without further operational or financial updates, this transaction alone suggests a 'hold' as it's a neutral to slightly positive development for Pelthos, but not a game-changer that warrants a strong buy or sell recommendation.

Keywords

Ligand Pharmaceuticals, Pelthos Therapeutics, Convertible Note, SEC Form 4, Insider Transaction, Biotech Investment, Securities Purchase Agreement